| Identification | Back Directory | [Name]
MK-8353 | [CAS]
1184173-73-6 | [Synonyms]
MK-8353
SCH900353
SCH-900565
MK-8353 (SCH900353)
3-Pyrrolidinecarboxamide, 1-[2-[3,6-dihydro-4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-1(2H)-pyridinyl]-2-oxoethyl]-N-[3-[6-(1-methylethoxy)-3-pyridinyl]-1H-indazol-5-yl]-3-(methylthio)-, (3S)- | [Molecular Formula]
C37H41N9O3S | [MOL File]
1184173-73-6.mol | [Molecular Weight]
691.84 |
| Chemical Properties | Back Directory | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
11.89±0.40(Predicted) | [color ]
Off-white to light brown | [InChIKey]
KPQQGHGDBBJGFA-QNGWXLTQSA-N | [SMILES]
N1(CC(N2CCC(C3=CC=C(C4N=CN(C)N=4)C=C3)=CC2)=O)CC[C@@](SC)(C(NC2C=CC3=C(C=2)C(C2=CC=C(OC(C)C)N=C2)=NN3)=O)C1 |
| Hazard Information | Back Directory | [Uses]
MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity. | [Definition]
ChEBI: MK-8353 is a member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of indazoles, a member of triazoles, a dihydropyridine, a member of pyridines, an aromatic ether, a secondary carboxamide, a pyrrolidinecarboxamide, a N-alkylpyrrolidine, a methyl sulfide and a tertiary carboxamide. | [in vivo]
MK-8353 (60 mg/kg, p.o., bid (twice daily)) causes at least 50% tumor growth inhibition or regression in 83% of the animal models bearing different tumor cells, including LOX, Colo-205, MIA PaCa-2, and Calu-6 cells[1]. | [IC 50]
ERK2: 8.8 nM (IC50); ERK1: 23 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Moschos SJ, et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 Feb 22;3(4). pii: 92352. DOI:10.1172/jci.insight.92352 |
|
|